Cargando...
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morbidity. Initial guidelines suggested lifelong treat...
Guardado en:
| Publicado en: | Pediatr Nephrol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6794245/ https://ncbi.nlm.nih.gov/pubmed/30402748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-018-4091-3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|